Document Detail


Azathioprine hepatotoxicity is uncommon in patients with Rheumatic diseases.
MedLine Citation:
PMID:  19078358     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
At present, there is no consensus regarding the utility of liver enzyme monitoring in rheumatology patients undergoing treatment with azathioprine (AZA). To further investigate this issue, we retrospectively reviewed for current or past use of AZA all patient records in our Disease Modifying Antirheumatic Drug (DMARD) clinic from May 1986 through September 1996. Information available from individual DMARD charts included AZA data (dates initiated, dose, indication for changing dose or stopping AZA), co-administered DMARDs, and aspartate aminotransferase (AST) serum values. In patients followed in the clinic through February 1994, serum alkaline phosphatase (AP) values additionally were available. Published reports of AZA hepatotoxicity in rheumatoid arthritis (RA) patients were found by a MEDLINE search, supplemented by a manual search of reference lists.We screened 429 patient records, and all patients who had received AZA at any time during the study period (n = 56) were identified for further review. The mean daily AZA dose was 96 mg (median = 100 mg/ day, range = 25-200 mg/day). All of the 56 patients had undergone routine periodic monitoring of serum AST while taking AZA (mean interval = 26 days); 30 of these patients additionally underwent monitoring of serum AP (mean interval = 24 days). Twenty-three (41%) of the patients had at least one episode of an abnormally elevated serum AST and/or AP while taking AZA. Only 1 of these 2 laboratory values was abnormal in 12 patients. The average time from AZA initiation to first appearance of an abnormal AST and/or AP value was 27 days (range = 7-62 days). During observation alone, all abnormal laboratory test results became normalized in 20 of 23 patients (87%) during the study period. There were no interventions in response to an abnormal laboratory value, and no patient experienced an adverse clinical outcome attributable to AZA hepatotoxicity during the 10-year study period.AZA use for rheumatic conditions may be associated with elevations in both the serum AST and/or AP values. Most of these elevations were transient, and none were clinically significant in our patient population. This study supports current American College of Rheumatology guidelines, which do not recommend routine periodic monitoring with liver enzyme tests in RA patients taking AZA. Furthermore, this study suggests that the utility of the baseline liver enzyme test in these patients is not well established.
Authors:
D R Griger; J B Higgs; D W Roane
Related Documents :
3486958 - Diagnosis of diffuse hepatocellular diseases using spect.
1975818 - Ursodeoxycholic acid for primary sclerosing cholangitis.
6198238 - Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the ...
19328938 - Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium...
1822448 - Luminol-dependent chemiluminiscence of monocytes and granulocytes in multiple sclerosis...
24447948 - Clinical experience with affinity pixie™ oxygenation system in paediatric and infant ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases     Volume:  5     ISSN:  1076-1608     ISO Abbreviation:  J Clin Rheumatol     Publication Date:  1999 Apr 
Date Detail:
Created Date:  2008-12-16     Completed Date:  2009-12-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9518034     Medline TA:  J Clin Rheumatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  60-4     Citation Subset:  -    
Affiliation:
David Grant Medical Center, Travis Air Force Base, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Pilot Study Employing Dehydroepiandrosterone (DHEA) in the Treatment of Chronic Fatigue Syndrome.
Next Document:  Conservative treatment of cervical radiculopathy.